Vaxcyte adds Moncef Slaoui to board

Vaxcyte, Inc. announced a planned change on its board of directors.

Rhea-AI Filing Summary

Vaxcyte, Inc. announced a planned change on its board of directors. On June 17, 2026, long‑serving director Jacks Lee retired from the board, with the company stating his retirement was not due to any disagreement or dispute. He will continue to support Vaxcyte under a consulting agreement focused on global strategic supply and manufacturing operations.

That same day, the board appointed Moncef Slaoui as a Class II independent director, effective immediately, with a term running until the 2028 annual stockholder meeting. He qualifies as an independent director under Nasdaq Rule 5605(a)(2), and the company reports no related‑party transactions requiring disclosure. Slaoui will be compensated under Vaxcyte’s non‑employee director compensation program, which currently sets the equivalent value of the annual equity grant for each director at $430,000, and he has entered into the company’s standard indemnification agreement.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Par value per share: $0.001 per share Annual equity grant value: $430,000 Director term end: 2028 +2 more

5 metrics

Par value per share $0.001 per share Common Stock par value

Annual equity grant value $430,000 Equivalent value of annual equity grant for each director

Director term end 2028 Moncef Slaoui’s Class II director term expires at 2028 annual meeting

Retirement effective date June 17, 2026 Effective date of Jacks Lee’s retirement from the board

Appointment effective date June 17, 2026 Effective date of Moncef Slaoui’s appointment to the board

Key Terms

independent director, Rule 5605(a)(2), Item 404(a) of Regulation S-K, non-employee director compensation program, +1 more

5 terms

independent director financial

"The Board has determined that Dr. Slaoui qualifies as an independent director under the independence requirements"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

Rule 5605(a)(2) regulatory

"independent director under the independence requirements set forth under Rule 5605(a)(2) of the Nasdaq Rules"

Item 404(a) of Regulation S-K regulatory

"there are no transactions involving the Company and Dr. Slaoui that the Company would be required to report pursuant to Item 404(a) of Regulation S-K"

non-employee director compensation program financial

"Dr. Slaoui will receive compensation in accordance with the Company’s non-employee director compensation program"

indemnification agreement legal

"The Company has entered into its standard form of indemnification agreement with Dr. Slaoui."

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board changes did Vaxcyte (PCVX) disclose on June 17, 2026?

Vaxcyte disclosed that director Jacks Lee retired from its board effective June 17, 2026. On the same date, the board appointed Moncef Slaoui as a Class II director, with his term running until the company’s 2028 annual meeting of stockholders.

Why did Vaxcyte director Jacks Lee retire from the board?

Vaxcyte stated that Jacks Lee’s retirement from the board was not the result of any disagreement or dispute with the company. Following his retirement, he entered into a consulting agreement to advise on global strategic supply and manufacturing operations.

Who is Moncef Slaoui and what role will he have at Vaxcyte (PCVX)?

Moncef Slaoui has been appointed as a Class II director on Vaxcyte’s board, effective June 17, 2026. His term will extend until the 2028 annual stockholder meeting, and the board has determined he qualifies as an independent director under Nasdaq rules.

Is Moncef Slaoui considered an independent director at Vaxcyte?

Yes. Vaxcyte’s board determined that Moncef Slaoui qualifies as an independent director under the independence requirements in Nasdaq Rule 5605(a)(2). The company also reported no transactions with him that require disclosure under Item 404(a) of Regulation S‑K.

How will Vaxcyte compensate new director Moncef Slaoui?

Moncef Slaoui will be compensated under Vaxcyte’s non‑employee director compensation program. The company notes that the equivalent value of the annual equity grant for all directors is currently set at $430,000, and he has also signed the standard indemnification agreement.

Does Vaxcyte report any related‑party transactions with Moncef Slaoui?

No. Vaxcyte states there are no transactions involving the company and Moncef Slaoui that would require disclosure under Item 404(a) of Regulation S‑K. It also notes there are no arrangements or understandings with others pursuant to which he was selected as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:09 PM EDT Learn about SEC filing dates

0001649094FALSE825 Industrial RoadSuite 300San CarlosCalifornia00016490942026-06-172026-06-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________________________________________

FORM 8-K

_____________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2026

_____________________________________________

Vaxcyte, Inc.

(Exact name of Registrant as Specified in Its Charter)

_____________________________________________

Delaware			01-39323			46-4233385
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
825 Industrial Road Suite 300 San Carlos, California						94070
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 837-0111

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_____________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

PCVX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 17, 2026, Jacks Lee notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of June 17, 2026. Mr. Lee’s retirement was not the result of any disagreement or dispute with the Company. The Company thanks Mr. Lee for his considerable contributions over the course of his Board service. Effective upon his retirement, Mr. Lee entered into a consulting agreement with the Company pursuant to which he will serve as a consultant to the Company on matters relating to global strategic supply and manufacturing operations.

On June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Moncef Slaoui to the Board as a Class II director, which appointment became effective immediately. Dr. Slaoui’s term will expire at the Company’s annual meeting of stockholders in 2028.

The Board has determined that Dr. Slaoui qualifies as an independent director under the independence requirements set forth under Rule 5605(a)(2) of the Nasdaq Rules and listing standards. There are no arrangements or understandings between Dr. Slaoui and any other persons pursuant to which he was selected as a director. Additionally, there are no transactions involving the Company and Dr. Slaoui that the Company would be required to report pursuant to Item 404(a) of Regulation S-K.

Dr. Slaoui will receive compensation in accordance with the Company’s non-employee director compensation program as in effect from time to time (the “Director Compensation Program”), as most recently described under the section titled “Non-Employee Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 23, 2026; provided, however, that the equivalent value of the annual equity grant for all directors is currently set at $430,000.

The Company has entered into its standard form of indemnification agreement with Dr. Slaoui.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

									VAXCYTE, INC.
Date:			June 23, 2026			By:			/s/ Andrew Guggenhime
									Andrew Guggenhime President and Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.7 KB